Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference Transcript
Good morning. Thanks, everyone, for joining us. I'm Salveen Richter, one of the Biotechnology Analysts at Goldman Sachs, and we're happy to have the Ultragenyx team with us this morning. With us, we have Emil Kakkis, the CEO, President and Founder of this firm.
Questions & Answers
So Emil, maybe just to start, at your R&D Day recently, you noted how RARE is now a global commercial company focused on 3 therapeutic areas and developing drugs in 4 therapeutic modalities. Can you just start by walking us through these areas? And how you think about prioritization of different modalities for indication disease?
Well, we decided to branch out and add gene therapy and mRNA to our original portfolio because there are certain diseases you just can't treat with proteins, additional protein
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |